The Medicines Company (MDCO) belonging to the Medical sector has declined -3.36% and closed its last trading session at $52.58.
The company reported its EPS on 02/28/2017. Currently, the stock has a 1 Year Price Target of $59.18.
The consensus recommendation, according to Zacks Investment research, is 1.13. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.13 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.13 and 1.14 respectively.
The Medicines Company on 02/28/2017 reported its EPS as $-1.75 with the analysts projecting the EPS of the stock as $-1.43. The company beat the analyst EPS Estimate with the difference of $-0.32. This shows a surprise factor of -22.4%.
Many analysts have provided their estimated foresights on The Medicines Company Earnings, with 7 analysts believing the company would generate an Average Estimate of $-1.3.
Whereas they predicted High and Low Earnings Estimate as $-1.06 and $-1.71 respectively. While in the same Quarter Previous year, the Actual EPS was $-1.34.
Analysts are also projecting an Average Revenue Estimate for The Medicines Company as $31.23 Million in the Current Quarter. This estimate is provided by 8 analysts.
The High Revenue estimate is predicted as 54.5 Million, while the Low Revenue Estimate prediction stands at 18.9 Million. The company’s last year sales total was 50.31 Million.
For the Current Quarter, the growth estimate for The Medicines Company is 3%, while for the Next Quarter the stock growth estimate is -149.2%.
In the past 5 years, the stock showed growth of -67.38% per annum. While for the next 5 years, the growth estimate is 72.9%.
The Company got Initiated by H.C. Wainwright on 5-Dec-16 to Buy.
Insider Trades for The Medicines Company show that the latest trade was made on 1 Mar 2017 where O’Connor (William Bernard), the Chief Financial Officer completed a transaction type “Sell” in which 4414 shares were traded at a price of $52.4.
17 Insider Sales transactions were made totaling 397840 shares traded.
11 analysts projected Price Targets for The Medicines Company. The analysts believe that the company stock price could grow as high as $80. The Low Price target projection by analysts is $39 and the Mean Price Target is $59.18.
The Medicines Company (MDCO) has the market capitalization of $3.77 Billion. The company rocked its 52-Week High of $55.28 on Mar 16, 2017 and touched its 52-Week Low of $29.48 on Mar 29, 2016.
The stock has Return on Assets (ROA) of -6.9 percent. Return on Equity (ROE) stands at -16.4% and Return on Investment (ROI) of -27.6 percent.
The stock is currently showing YTD performance of 54.92 Percent. The company has Beta Value of 0.75 and ATR value of 2.03. The Weekly and Monthly Volatility stands at 3.99% and 3.75%.